Re:""The other important thing that investors need to realize is that the business model for stem cell companies is still a bit of an enigma," said Weintraub. "The business model of selling someone their own cells is still uncertain. It's not like a drug that you can sell someone for $40,000 a year.""
Well, Weintraub, for one, you can sell them the process.
After all, a person can pile up their fingernails, but unless they know how to culture and clone them, won't do much good, will it.
Although the article was about stem cells, GERN has more than that going for it, (vaccines, for instance), patents on processes, as well as being set up overseas...they left that part out, for some reason.
And, if the processes work, and all else fails, business-wise, one of those big pharmas with the cash can buy GERN.
Best,
S. |
